{"title":"血液病患者流感病毒感染的危险因素","authors":"Hirotomo Nakashima, Shin-Ichiro Fujiwara, Seina Honda, Ryutaro Tominaga, Daizo Yokoyama, Atsuto Noguchi, Shuka Furuki, Shunsuke Koyama, Rui Murahashi, Takashi Ikeda, Kazuki Hyodo, Shin-Ichiro Kawaguchi, Yumiko Toda, Kento Umino, Daisuke Minakata, Masahiro Ashizawa, Chihiro Yamamoto, Kaoru Hatano, Kazuya Sato, Ken Ohmine, Yoshinobu Kanda","doi":"10.1080/10428194.2025.2495106","DOIUrl":null,"url":null,"abstract":"<p><p>Influenza virus infections (IVIs) are an important cause of complications and death in immunocompromised patients, but the incidence and risk factors for IVIs in hematological diseases including benign diseases are not fully understood. We retrospectively investigated IVIs in patients with hematological diseases who visited our hematology outpatient department between 2012 and 2019. In 4,864 outpatients, 81(1.67%) IVIs were identified. The incidence of IVIs was 4.82 (95% confidence interval [CI], 3.85-5.96) per 1,000 person-years, with significantly higher rates in post-allogeneic transplant patients (21.0, 95% CI, 12.8-32.5). Progression to lower respiratory tract infection (LRTI) was observed in 7 (8.6%) of 81 patients with IVIs. In a univariate logistic regression analysis, LTRI was associated with age ≥60 years and moderate to severe chronic GVHD. Patients after hematopoietic stem cell transplantation may be at a higher risk for IVIs. Advanced age exacerbated the effects of IVIs on hematological diseases.</p>","PeriodicalId":18047,"journal":{"name":"Leukemia & Lymphoma","volume":" ","pages":"1675-1681"},"PeriodicalIF":2.2000,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Risk factors for influenza virus infection in patients with hematological disease.\",\"authors\":\"Hirotomo Nakashima, Shin-Ichiro Fujiwara, Seina Honda, Ryutaro Tominaga, Daizo Yokoyama, Atsuto Noguchi, Shuka Furuki, Shunsuke Koyama, Rui Murahashi, Takashi Ikeda, Kazuki Hyodo, Shin-Ichiro Kawaguchi, Yumiko Toda, Kento Umino, Daisuke Minakata, Masahiro Ashizawa, Chihiro Yamamoto, Kaoru Hatano, Kazuya Sato, Ken Ohmine, Yoshinobu Kanda\",\"doi\":\"10.1080/10428194.2025.2495106\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p>Influenza virus infections (IVIs) are an important cause of complications and death in immunocompromised patients, but the incidence and risk factors for IVIs in hematological diseases including benign diseases are not fully understood. We retrospectively investigated IVIs in patients with hematological diseases who visited our hematology outpatient department between 2012 and 2019. In 4,864 outpatients, 81(1.67%) IVIs were identified. The incidence of IVIs was 4.82 (95% confidence interval [CI], 3.85-5.96) per 1,000 person-years, with significantly higher rates in post-allogeneic transplant patients (21.0, 95% CI, 12.8-32.5). Progression to lower respiratory tract infection (LRTI) was observed in 7 (8.6%) of 81 patients with IVIs. In a univariate logistic regression analysis, LTRI was associated with age ≥60 years and moderate to severe chronic GVHD. Patients after hematopoietic stem cell transplantation may be at a higher risk for IVIs. Advanced age exacerbated the effects of IVIs on hematological diseases.</p>\",\"PeriodicalId\":18047,\"journal\":{\"name\":\"Leukemia & Lymphoma\",\"volume\":\" \",\"pages\":\"1675-1681\"},\"PeriodicalIF\":2.2000,\"publicationDate\":\"2025-09-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Leukemia & Lymphoma\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1080/10428194.2025.2495106\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2025/4/24 0:00:00\",\"PubModel\":\"Epub\",\"JCR\":\"Q3\",\"JCRName\":\"HEMATOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Leukemia & Lymphoma","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1080/10428194.2025.2495106","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/4/24 0:00:00","PubModel":"Epub","JCR":"Q3","JCRName":"HEMATOLOGY","Score":null,"Total":0}
Risk factors for influenza virus infection in patients with hematological disease.
Influenza virus infections (IVIs) are an important cause of complications and death in immunocompromised patients, but the incidence and risk factors for IVIs in hematological diseases including benign diseases are not fully understood. We retrospectively investigated IVIs in patients with hematological diseases who visited our hematology outpatient department between 2012 and 2019. In 4,864 outpatients, 81(1.67%) IVIs were identified. The incidence of IVIs was 4.82 (95% confidence interval [CI], 3.85-5.96) per 1,000 person-years, with significantly higher rates in post-allogeneic transplant patients (21.0, 95% CI, 12.8-32.5). Progression to lower respiratory tract infection (LRTI) was observed in 7 (8.6%) of 81 patients with IVIs. In a univariate logistic regression analysis, LTRI was associated with age ≥60 years and moderate to severe chronic GVHD. Patients after hematopoietic stem cell transplantation may be at a higher risk for IVIs. Advanced age exacerbated the effects of IVIs on hematological diseases.
期刊介绍：
Leukemia & Lymphoma in its fourth decade continues to provide an international forum for publication of high quality clinical, translational, and basic science research, and original observations relating to all aspects of hematological malignancies. The scope ranges from clinical and clinico-pathological investigations to fundamental research in disease biology, mechanisms of action of novel agents, development of combination chemotherapy, pharmacology and pharmacogenomics as well as ethics and epidemiology. Submissions of unique clinical observations or confirmatory studies are considered and published as Letters to the Editor
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
